Journal article
(Re)defining legitimacy in Canadian drug assessment policy? Comparing ideas over time
Abstract
How do experts judge the legitimacy of technical policy processes, and do their ideas change as these processes are opened to other stakeholders and the public? This research examines the adoption of public and patient involvement in pharmaceutical assessment in Canada. It finds tensions between scientific legitimacy that prioritizes rigor and objectivity, and democratic legitimacy that values inclusion and a broader range of evidence. In …
Authors
Boothe K
Journal
Health Economics Policy and Law, Vol. 16, No. 4, pp. 424–439
Publisher
Cambridge University Press (CUP)
Publication Date
October 2021
DOI
10.1017/s1744133121000013
ISSN
1744-1331